By: Andrea S. Blevins Primeau
Adding isatuximab to carfilzomib and dexamethasone does not improve overall survival in patients with relapsed/refractory multiple myeloma, data from the IKEMA trial suggest.
Andrea S is a writer and producer who has contributed to various publications in the medical field. With a focus on oncology and other medical specialties, Andrea's work covers topics such as cancer treatments, clinical trials, telehealth, and alternative medicine. Her articles aim to provide valuable insights and information to healthcare professionals and patients alike.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
This information evolves through artificial intelligence and human feedback. Improve this profile .